WEST VIRGINIA LEGISLATURE

2024 REGULAR SESSION

Enrolled

2024 HAR 27 A 10: 04

Committee Substitute

for

Committee Substitute

for

Senate Bill 325

BY SENATORS TAKUBO, PLYMALE, WOODRUM, WOELFEL,

WELD, HAMILTON, AND DEEDS

[Passed March 8, 2024; in effect 90 days from

passage (June 6, 2024)]

SB 325

WEST VIRGINIA LEGISLATURE

2024 REGULAR SESSION

Enrolled

Committee Substitute

DEAL WAR 21 A 10: OH DEFLICE OF WEST VIRGINIA

for

Committee Substitute

for

Senate Bill 325

BY SENATORS TAKUBO, PLYMALE, WOODRUM, WOELFEL,

WELD, HAMILTON, AND DEEDS

[Passed March 8, 2024; in effect 90 days from

passage (June 6, 2024)]

Enr CS for CS for SB 325

- 1 AN ACT to amend the Code of West Virginia, 1931, as amended, by adding thereto a new section,
- 2 designated §60A-8-6a, relating to the distribution of drugs to safety net providers and
- 3 contract pharmacies; defining terms; penalties; promulgation of rules; and preemption.

Be it enacted by the Legislature of West Virginia:

ARTICLE 8. WHOLESALE DRUG DISTRIBUTION LICENSING ACT OF 1991.

§60A-8-6a. Distribution of safety net drugs to contract pharmacies; penalties; and preemption.

- 1 (a) *Definitions*. As used in this section:
- 2 (1) "340B drug" means a drug that:
- 3 (A) Is a covered outpatient drug within the meaning of 42 U.S.C. §256b;
- 4 (B) Has been subject to any offer for reduced prices by a manufacturer under 42 U.S.C.
- 5 §256b(a)(1); and
- 6 (C) Is purchased by a covered entity within the meaning of 42 U.S.C. §256b.
- 7 (2) "340B entity" has the same meaning as that term is defined in §33-51-3 of this code.
- 8 (3) "Biological product" has the same meaning as that term is defined in 42 U.S.C. §262.
- 9 (4) "Board of Pharmacy" means the West Virginia Board of Pharmacy, which is the agency

10 of this state authorized to issue and condition licensure and permitting of wholesale drug

- 11 distributors, third-party logistics providers, and manufacturers.
- (5) "Commissioner" means the West Virginia Insurance Commissioner, his or her
 deputies, or the West Virginia Offices of the Insurance Commissioner.
- 14 (6) "Manufacturer" has the same meaning as that term is defined in §60A-8-5 of this code,
- 15 except that such definition shall include manufacturers of biological products.
- 16 (7) "Package" has the same meaning as that term is defined in 21 U.S.C. §360eee(11)(A).
- 17 (8) "Pharmacy" has the same meaning as that term is defined in §30-5-4 of this code.
- 18 (b) Distribution of drugs to safety net providers and contract pharmacies. —

Enr CS for CS for SB 325

(1) A manufacturer, agent, or affiliate of such manufacturer shall not, either directly or
indirectly, deny, restrict, or prohibit the acquisition of a 340B drug by, or delivery of a 340B drug
to, a location authorized by a 340B entity to receive such 340B drug, unless the receipt of the
340B drug is prohibited by the United States Department of Health and Human Services.

(2) A manufacturer, agent, or affiliate of such manufacturer shall not, either directly or
indirectly, require a 340B entity to submit any claims or utilization data as a condition for allowing
the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity unless the claims
or utilization data sharing is required by the United States Department of Health and Human
Services.

28 (c) Penalties and investigations. —

29 (1) The commission of any act prohibited by subsection (b) of this section constitutes:

30 (A) A violation of §46A-6-104 of this code and shall subject the violator to a civil penalty of
31 \$50,000 per each violation, as well as any and all actions, including investigative demands,
32 remedies, and penalties provided for in §46A-7-101 *et seq.* of this code, except that there shall
33 be no right to bring a private cause of action; and

(B) A violation of §33-11-1 *et seq.* of this code and shall subject the violator to any and all
actions, including cease and desist orders, civil penalties, and restitution provided for in §33-116 of this code, except that there shall be no right to bring a private cause of action.

37 (2) Each package of 340B drugs determined to be subject to a prohibited act under
 38 subsection (b) of this section constitutes a separate violation under this section.

39 (3) Upon receipt by the Board of Pharmacy of a complaint that a manufacturer has violated
40 subsection (b) of this section, the Board of Pharmacy:

(A) May investigate the complaint, including by investigating the manufacturer or any
 agent, affiliate, or contractor thereof, including any wholesaler or third-party logistics provider that
 may possess evidence supporting such complaint; and

Enr CS for CS for SB 325

- 44 (B) Shall consider appropriate penalties, including imposing discipline, or suspending, or
- 45 revoking the license or permit of any manufacturer; and
- 46 (C) Shall share the results of the investigation with the Attorney General and commissioner
- 47 if an investigation is conducted.
- 48 (3) The Board of Pharmacy and commissioner may promulgate rules to implement the49 provisions of subsection (b) of this section.
- 50 (d) Preemption. —
- (1) Nothing in this section is to be construed or applied to be less restrictive than any
 federal law as to any person or other entity regulated by this section. Nothing in this section is to
 be construed or applied to be in conflict with any of the following:
- 54 (A) Applicable federal law and related regulations.
- 55 (B) Other laws of this state, if the state law is compatible with applicable federal law.
- 56 (2) Limited distribution of a drug required under 21 U.S.C. §355-1 is not to be construed

57 as a violation of this section.

.

The Clerk of the Senate and the Clerk of the House of Delegates hereby certify that the foregoing bill is correctly enrolled.

Clerk of the Senate

Clerk of the House of Delegates

Originated in the Senate.

In effect 90 days from passage.

President of the Senate

Speaker of the House of Delegates

2024

27th The within is this the...... Day of 2024. Governor

PRESENTED TO THE GOVERNOR